Clinical Trial Detail

NCT ID NCT01741753
Title BKM120+Abiraterone Acetate for Metastatic CRPC
Recruitment Terminated
Gender male
Phase Phase I
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

prostate cancer

Therapies

Abiraterone + Buparlisib + Prednisone

Age Groups: adult

No variant requirements are available.